Literature DB >> 18487570

Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity?

Nancy L Keating1, Mary Beth Landrum, Carrie N Klabunde, Robert H Fletcher, Selwyn O Rogers, William R Doucette, Diana Tisnado, Steven Clauser, Katherine L Kahn.   

Abstract

PURPOSE: We surveyed cancer physicians to understand how patients' age and comorbidity influence adjuvant chemotherapy recommendations and whether physician or practice characteristics also affect these recommendations.
METHODS: National survey of surgeons and medical oncologists caring for patients with colorectal cancer regarding whether they would recommend adjuvant chemotherapy for hypothetical patients with stage III colon cancer who varied by age (55 v 80 years) and comorbid illness (none, moderate, severe congestive heart failure [CHF]). Repeated measures logistic regression was used to assess the influence of patient, physician, and practice characteristics on chemotherapy recommendations.
RESULTS: Of 1,096 physicians, nearly all recommended chemotherapy for patients who were 55 years old with no comorbidity (99.0%), 55-years old with moderate CHF (88.6%), or 80 years old with no comorbidity (92.6%); many fewer recommended chemotherapy for 55-year-old patients with severe CHF (24.9%) or 80-year-old patients with moderate (47.2%) or severe (9.0%) CHF (P < .001). Younger physicians (P < .001) were more likely than others to recommend adjuvant chemotherapy overall, although physician factors explained little of the variability in recommendations.
CONCLUSION: Physicians agree with guidelines recommending adjuvant chemotherapy for young, healthy patients with stage III colon cancer but differ widely on recommendations for patients who are older and sicker. Few physician or practice characteristics were associated with recommendations. For older and sicker patients, the individual physicians seen may have a substantial impact on the likelihood of receiving chemotherapy. Understanding better the sources of variation not explained by patients' clinical characteristics may allow improved tailoring of therapy to patients most likely to benefit.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487570     DOI: 10.1200/JCO.2007.15.9434

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  48 in total

1.  How do oncologists make decisions about chemotherapy for their older patients with cancer? A survey of Australian oncologists.

Authors:  E B Moth; B E Kiely; V Naganathan; A Martin; P Blinman
Journal:  Support Care Cancer       Date:  2017-08-03       Impact factor: 3.603

Review 2.  Systemic therapies for metastatic renal cell carcinoma in older adults.

Authors:  Sumanta K Pal; Ari Vanderwalde; Arti Hurria; Robert A Figlin
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

3.  Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?

Authors:  Diana Tisnado; Jennifer Malin; Katherine Kahn; Mary Beth Landrum; Robert Fletcher; Carrie Klabunde; Steven Clauser; Selwyn O Rogers; Nancy L Keating
Journal:  J Oncol Pract       Date:  2016-06-07       Impact factor: 3.840

4.  Utilization of bevacizumab in US elderly patients with colorectal cancer receiving chemotherapy.

Authors:  Alex Z Fu; Huei-Ting Tsai; John L Marshall; Andrew N Freedman; Arnold L Potosky
Journal:  J Oncol Pharm Pract       Date:  2013-10-11       Impact factor: 1.809

5.  Chemotherapy use and patient treatment preferences in advanced colorectal cancer: a prospective cohort study.

Authors:  S Yousuf Zafar; Jennifer L Malin; Steven C Grambow; David H Abbott; Jane T Kolimaga; Leah L Zullig; Jane C Weeks; John Z Ayanian; Katherine L Kahn; Patricia A Ganz; Paul J Catalano; Dee W West; Dawn Provenzale
Journal:  Cancer       Date:  2012-09-12       Impact factor: 6.860

6.  Oncologists' perspectives on post-cancer treatment communication and care coordination with primary care physicians.

Authors:  C N Klabunde; D Haggstrom; K L Kahn; S W Gray; B Kim; B Liu; J Eisenstein; N L Keating
Journal:  Eur J Cancer Care (Engl)       Date:  2017-01-10       Impact factor: 2.520

7.  The effect of comorbidities on outcomes in colorectal cancer survivors: a population-based cohort study.

Authors:  Colleen A Cuthbert; Brenda R Hemmelgarn; Yuan Xu; Winson Y Cheung
Journal:  J Cancer Surviv       Date:  2018-09-06       Impact factor: 4.442

8.  Competing nomograms help in the selection of elderly patients with colon cancer for adjuvant chemotherapy.

Authors:  Dan Li; Chenhan Zhong; Xiujun Tang; Linzhen Yu; Kefeng Ding; Ying Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2018-02-19       Impact factor: 4.553

9.  Decision-making by surgeons about referral for adjuvant therapy for patients with non-small-cell lung, breast or colorectal cancer: a qualitative study.

Authors:  Robin Urquhart; Cynthia Kendell; Gordon Buduhan; Daniel Rayson; Joan Sargeant; Paul Johnson; Eva Grunfeld; Geoffrey A Porter
Journal:  CMAJ Open       Date:  2016-01-12

Review 10.  Treatment of colorectal cancer in older patients.

Authors:  Riccardo A Audisio; Demetris Papamichael
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-10-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.